Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy
Mitochondrion · 2026-07 · 89 · 102138
DOI: 10.1016/j.mito.2026.102138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mitochondrion, 2026-07. Verfasst von Hacer Durmus und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: hacer.durmus@istanbul.edu.tr. Hauptthemen laut MEDLINE: Thymidine Kinase, Mitochondrial Myopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the long-term efficacy and safety of deoxynucleoside therapy in adult patients with late-onset thymidine kinase 2 deficiency (TK2d). BACKGROUND: TK2d is a mitochondrial myopathy causing progressive weakness, respiratory insufficiency, and early mortality. While nucleoside supplementation benefits pediatric cases, evidence in adults remains limited. METHODS: Six genetically confirmed adults with TK2d were treated under compassionate-use protocols in Turkey, receiving escalating doses of oral or PEG-administered Doxecitine and Doxribtimine up to 800 mg/kg/day. Functional and clinical outcomes included the 6-minute walk test (6MWT), Hammersmith Functional Motor Scale Expanded (HFMSE), forced vital capacity (FVC), Fatigue Severity Scale (FSS), and body mass index (BMI). RESULTS: Over a median follow-up of 24 (range 6-36) months, therapy was associated with sustained functional and respiratory improvements. Mean 6MWT increased from 152 m at baseline to 468 m at 24 months and exceeded 600 m in patients with 36-month data. The mean HFMSE increased from 20.5 at baseline to 24.5 at 3 months, 29 at 6 months. Patients with the longest follow-up reached a mean HFMSE of 58 at 36 months. FVC, which had declined before treatment, stabilized or improved in all patients (mean increase from 36% to 55.6% at 36 months). The youngest patient achieved near-normal respiratory function. Fatigue severity decreased by ∼ 30%, and BMI improved notably in underweight individuals. Treatment was generally well tolerated; transient liver enzyme elevations and mild gastrointestinal side effects resolved spontaneously. CONCLUSIONS: Deoxynucleoside therapy appears effective and well tolerated in adults with TK2d, producing sustained functional and respiratory gains. Early treatment initiation is crucial to maximize benefit; though partial improvements may occur even in advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey. Electronic address: hacer.durmus@istanbul.edu.tr.
- Institute of Child Health, Department of Pediatric Basic Sciences, Division of Medical Genetics, Istanbul University, Turkey.
- Intergen Genetic Center, Ankara, Turkey.
- Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
- Department of Pulmonology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Zitieren
APA
Durmus, H., Gedikbaşı, A., Ceylaner, S., Çakar, A., Mergen, S., Kıyan, E., & Parman, Y. G. (2026). Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy. Mitochondrion, 89, 102138. https://doi.org/10.1016/j.mito.2026.102138
Vancouver
Durmus H, Gedikbaşı A, Ceylaner S, Çakar A, Mergen S, Kıyan E, et al. Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy. Mitochondrion. 2026;89:102138. doi:10.1016/j.mito.2026.102138
BibTeX
@article{Durmus2026,
author = {Durmus, Hacer and Gedikbaşı, Asuman and Ceylaner, Serdar and Çakar, Arman and Mergen, Sezan and Kıyan, Esen and Parman, Yesim Gülşen},
title = {Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy},
journal = {Mitochondrion},
year = {2026},
volume = {89},
pages = {102138},
doi = {10.1016/j.mito.2026.102138}
}
EUVIMED